Nicola Battelli

Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients

Mirco Pistelli, M. De Lisa, Z. Ballatore et al. · BMC Cancer · 2015 · 121 citations · Full text

Medicine, Immunology, Oncology +15

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Marta Pestrin, Silvia Bessi, Fabio Puglisi et al. · Breast Cancer Research and Treatment · 2012 · 109 citations

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations

Mirco Pistelli, Miriam Caramanti, Tommasina Biscotti et al. · Cancers · 2014 · 88 citations · Full text

Medicine, Cancer Biology, Oncology +16

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer

Francesco Graziano, Vincenzo Catalano, Anna Maria Baldelli et al. · Annals of Oncology · 2000 · 86 citations · Full text

Medicine, Oncology, Pharmacotherapy +12